Physician profile
Angela Fishman
NPI 1437235983
$6,207.71
in general payments reported to CMS, 2019-2025
27 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $224 · 2021: $256 · 2022: $568 · 2023: $1,193 · 2024: $1,455 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,655 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,655.05 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,664.62 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.89 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $342.25 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $284.32 | 2019-2024 | |
| Olympus America INC. | $284.04 | 2020-2025 | Gastrointestinal Videoscope, Evis Exera III Xenon Light Source, Evis Exera III Colonovideoscope |
| Novo Nordisk INC | $281.42 | 2023 | |
| Qol Medical, LLC | $270.28 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $241.32 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $180.34 | 2024-2025 | |
| Madrigal Pharmaceuticals | $119.25 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $110.85 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $94.59 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $92.40 | 2023-2024 | Linzess |
| Pfizer INC. | $87.73 | 2023-2024 | |
| Fujifilm Healthcare Americas Corporation | $85.82 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.93 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $70.42 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $58.46 | 2024-2025 | Vowst |
| Celgene Corporation | $49.58 | 2022-2024 | Zeposia |
| Allergan, INC. | $47.87 | 2019 | |
| Braintree Laboratories, INC. | $41.19 | 2025 | Suflave |
| Ferring Pharmaceuticals INC. | $39.74 | 2022-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $27.30 | 2025 | |
| Fresenius Kabi USA, LLC | $20.64 | 2023 | Idacio |
| Daiichi Sankyo INC. | $16.55 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.23 | 2025 | Sutab |
| Phathom Pharmaceuticals, INC. | $8.68 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.